Medivir Hep C Drug Cures 80% of Patients Post-Treatment

Medivir AB’s experimental hepatitis C treatment TMC435 cured as many as 80 percent of patients 24 weeks after treatment ended, suggesting that the therapy prevents the virus from surging back.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.